Analystreport

Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) is now covered by analysts at KeyCorp. They set an "overweight" rating and a $10.72 price target on the stock.

Eiger BioPharmaceuticals, Inc.  (EIGR) 
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.eigerbio.com